| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | PSM; GCP3; FOLH2; FOLHP; PSMAL; GCPIII; PSMA-LIKE |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human FOLH1B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与FOLH1B(或PSMA)抗体相关的参考文献摘要，因FOLH1B可能为FOLH1(PSMA)的亚型或相关基因，部分文献基于PSMA研究：
---
1. **文献名称**: *Prostate-specific membrane antigen (PSMA): Current clinical utility in prostate cancer and future perspectives*
**作者**: Wright GL et al.
**摘要**: 探讨PSMA作为前列腺癌诊疗靶点的临床价值，详述其抗体在成像诊断(如PSMA-PET)及靶向治疗(如抗体药物偶联物)中的应用机制。
2. **文献名称**: *Antibody-drug conjugates targeting PSMA in metastatic castration-resistant prostate cancer*
**作者**: Tagawa ST et al.
**摘要**: 研究针对PSMA的抗体偶联药物(如177Lu-PSMA-617)在去势抵抗性前列腺癌中的疗效，验证抗体特异性结合及肿瘤细胞杀伤效果。
3. **文献名称**: *Differential expression of FOLH1 (PSMA) in tumor-associated neovasculature: Implications for therapeutic targeting*
**作者**: Chang SS et al.
**摘要**: 分析FOLH1在实体瘤新生血管中的特异性表达，提出利用其抗体进行血管靶向治疗的可能性，并验证抗体在体内外的靶向性。
---
注：FOLH1B可能与FOLH1/PSMA高度同源，若需精确区分，建议通过UniProt或NCBI Gene数据库确认基因/蛋白命名后再筛选文献。
The FOLH1B antibody targets the FOLH1B protein, a member of the folate hydrolase (FOLH) family, also known as prostate-specific membrane antigen (PSMA) or glutamate carboxypeptidase II (GCPII). FOLH1B is a splice variant of the FOLH1 gene, sharing structural similarities with the well-characterized FOLH1/PSMA protein, including a transmembrane domain and enzymatic activity. It functions as a type II transmembrane glycoprotein with carboxypeptidase activity, involved in folate digestion, neuropeptide processing, and possibly cell signaling.
FOLH1B has garnered attention due to its restricted overexpression in certain cancers, particularly prostate cancer, where it serves as a biomarker and therapeutic target. Unlike FOLH1/PSMA, FOLH1B’s expression profile and biological roles remain less defined, though studies suggest it may contribute to tumor progression or metastasis. Antibodies against FOLH1B are primarily used in research to elucidate its expression patterns, physiological functions, and pathological implications. They also hold potential for diagnostic applications (e.g., immunohistochemistry) and therapeutic strategies, such as antibody-drug conjugates or radioimmunotherapy targeting PSMA-related malignancies. However, cross-reactivity with FOLH1/PSMA requires careful validation to ensure specificity in experimental or clinical settings. Ongoing research aims to clarify its distinct roles and optimize FOLH1B-targeted interventions.
×
